Clinical-pharmacological evaluation of a new beta blocker, GYKI-41099 (tobanum).

Abstract

The acute and chronic circulatory effects of a new beta adrenergic blocking drug, dl-1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol hydrochloride, GYKI-41099, have been assessed in patients with hyperkinetic circulation/or mild hypertension. The acute effects of GYKI-41099 2.5, 5 and 10 mg have been compared with those of propranolol 10, 20 and 40 mg using a cross-over design in 18 patients with elevated cardiac index. Each dose of both drugs produced a significant reduction in sitting and exercise heart rate. The potency of GYKI-41099 compared with propranolol proved to be 3:1. 13 patients with hyperkinetic circulation on GYKI-41099 5-15 mg daily for 2 months exhibited a significant reduction in resting heart rate and cardiac index. In 13 patients with mild hypertension the drug exerted marked antihypertensive effect. Side effects were minimal and short-lived.

• Authors: E Török, M Istvánffy, M Halmágyi, M Wagner, M Csukás
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 18 Issue 5 Pg. 200-7 ( 1980) ISSN: 0174-4879 [Print] Germany
• PMID: 6104634 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Propanolamines
• Propranolol
• tobanum

Topics

• Adolescent
• Adrenergic beta-Antagonists (therapeutic use)
• Adult
• Blood Pressure (drug effects)
• Cardiac Output (drug effects)
• Clinical Trials as Topic
• Female
• Heart Rate (drug effects)
• Hemodynamics (drug effects)
• Humans
• Hypertension (drug therapy)
• Male
• Physical Exertion
• Propanolamines (therapeutic use)
• Propranolol (therapeutic use)
• Time Factors